All In MedTech

FDA Clearance Tracker · P860022

BOSTON EQUALENS (ITAFLUROFOCON A)/EQUALENS II (OPRIFOCON A) RIGID GAS PERMEABLE CONTACT LENS

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Nov 30, 1987 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Nov 30, 1987

Approved

Time to decision

546 days

Received Jun 2, 1986. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P860022
Device name
BOSTON EQUALENS (ITAFLUROFOCON A)/EQUALENS II (OPRIFOCON A) RIGID GAS PERMEABLE CONTACT LENS
Applicant
Bausch & Lomb
Applicant location
Rochester, NY
Received
Jun 2, 1986
Decided
Nov 30, 1987
Decision
Approved
Supplements
57 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III
Regulation
21 CFR 886.5916
Specialty
Ophthalmology

Every decision under product code MWL

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code MWL. The earliest in FDA's data is P850038, decided Dec 31, 1986.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Bausch & Lomb

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.